A JAK/STAT-Mediated Inflammatory Signaling Cascade Drives Oncogenesis In AF10-Rearranged AML
暂无分享,去创建一个
S. Chanda | S. Armstrong | T. Haferlach | I. Jeremias | C. Eaves | R. Levine | S. Meshinchi | Z. Ronai | R. Wechsler-Reya | P. Adams | D. Frank | M. Kleppe | A. Deshpande | A. Campos | A. Bagchi | Bo-Rui Chen | Karina Barbosa | Anagha Deshpande | Xue Li | Narayana Yeddula
[1] B. Druker,et al. Response and Resistance to BCR-ABL1-Targeted Therapies. , 2020, Cancer cell.
[2] M. Santoro,et al. RET Gene Fusions in Malignancies of the Thyroid and Other Tissues , 2020, Genes.
[3] Pavel Sumazin,et al. Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. , 2019, Blood advances.
[4] A. Drilon. TRK inhibitors in TRK fusion-positive cancers. , 2019 .
[5] S. Turner,et al. The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis , 2019, Cancers.
[6] Jesse R. Dixon,et al. Acute myeloid leukemia driven by the CALM-AF10 fusion gene is dependent on BMI1. , 2019, Experimental hematology.
[7] Emanuel J. V. Gonçalves,et al. Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening , 2019, Nature Communications.
[8] Kendall R. Sanson,et al. Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities , 2018, Nature Communications.
[9] S. Armstrong,et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. , 2018, Blood.
[10] Jihoon Kim,et al. PinAPL-Py: A comprehensive web-application for the analysis of CRISPR/Cas9 screens , 2017, Scientific Reports.
[11] K. Winthrop. The emerging safety profile of JAK inhibitors in rheumatic disease , 2017, Nature Reviews Rheumatology.
[12] Luca Pinello,et al. Integrated design, execution, and analysis of arrayed and pooled CRISPR genome-editing experiments , 2017, Nature Protocols.
[13] K. Winthrop. The emerging safety profile of JAK inhibitors in rheumatic disease , 2017, Nature Reviews Rheumatology.
[14] Neville E Sanjana,et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening , 2016, Nature Protocols.
[15] B. Geoerger,et al. Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine , 2017, Molecular therapy. Nucleic acids.
[16] J. Byrd,et al. Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia , 2017, British journal of haematology.
[17] Traci M. Blonquist,et al. Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. , 2016, Blood.
[18] E. Macintyre,et al. NAP1L1‐MLLT10 is a rare recurrent translocation that is associated with HOXA activation and poor treatment response in T‐cell acute lymphoblastic leukaemia , 2016, British Journal of Haematology.
[19] D. Wechsler,et al. A Critical Role for CRM1 in Regulating HOXA Gene Transcription in CALM-AF10 Leukemias , 2014, Leukemia.
[20] H. Kantarjian,et al. Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation. , 2015, Clinical lymphoma, myeloma & leukemia.
[21] S. Armstrong,et al. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. , 2014, Cancer cell.
[22] Joshua M. Weiss,et al. Effects of iron depletion on CALM-AF10 leukemias. , 2014, Experimental hematology.
[23] B. van Steensel,et al. Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.
[24] S. Chiaretti,et al. DDX3X-MLLT10 fusion in adults with NOTCH1 positive T-cell acute lymphoblastic leukemia , 2014, Haematologica.
[25] O. Bernard,et al. Identification of GSX2 and AF10 as NUP98 partner genes in myeloid malignancies , 2013, Blood Cancer Journal.
[26] C. Mecucci,et al. New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia. , 2013, Blood.
[27] D. Wechsler,et al. A CALM-derived nuclear export signal is essential for CALM-AF10-mediated leukemogenesis. , 2013, Blood.
[28] F. Locatelli,et al. Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia , 2013, Leukemia.
[29] J. Dipersio,et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis , 2013, British journal of haematology.
[30] J. Hess,et al. The pathogenesis of mixed-lineage leukemia. , 2012, Annual review of pathology.
[31] R. Arceci. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study , 2010 .
[32] S. Raimondi,et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. , 2009, Blood.
[33] P. Aplan,et al. The role of CALM–AF10 gene fusion in acute leukemia , 2008, Leukemia.
[34] W. Pear,et al. Tribbles homolog 2 (Trib2) and HoxA9 cooperate to accelerate acute myelogenous leukemia. , 2008, Blood cells, molecules & diseases.
[35] Scott A. Armstrong,et al. MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.
[36] A. Kustanovich,et al. Translocation (10;11)(p12;q23) in childhood acute myeloid leukemia: incidence and complex mechanism. , 2006, Cancer genetics and cytogenetics.
[37] Yi Zhang,et al. Leukaemic transformation by CALM–AF10 involves upregulation of Hoxa5 by hDOT1L , 2006, Nature Cell Biology.
[38] James R. Downing,et al. Annual review of pathology : mechanisms of disease , 2006 .
[39] W. Kamps,et al. The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. , 2006, Haematologica.
[40] E. Macintyre,et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRγδ lineage , 2003 .
[41] E. Macintyre,et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. , 2003, Blood.
[42] C. Sawyers. Rational therapeutic intervention in cancer: kinases as drug targets. , 2002, Current opinion in genetics & development.
[43] 公文 和子. Mixed-lineage leukemia with t(10;11)(p13;q21) : an analysis of AF10-CALM and CALM-AF10 fusion mRNAs and clinical features , 2000 .
[44] Y. Kaneko,et al. Mixed‐lineage leukemia with t(10;11)(p13;q21): An analysis of AF10‐CALM and CALM‐AF10 fusion mRNAs and clinical features , 1999, Genes, chromosomes & cancer.
[45] W. Hiddemann,et al. MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis. , 1998, Blood.